Cited by 659CAR-T cell therapy researchImmunotherapy and Immune ResponsesCRISPR and Genetic Engineering

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Open access

Ruella, Marco, Xu, Jun, Barrett, David M., Fraietta, Joseph A., Reich, Tyler J., Ambrose, David E., Klichinsky, Michael, Shestova, Olga, Patel, Prachi R., Kulikovskaya, Irina, Nazimuddin, Farzana, Bhoj, Vijay G., Orlando, Elena J., Fry, Terry J., Bitter, Hans, Maude, Shannon L., Levine, Bruce L., Nobles, Christopher L., Bushman, Frederic D., Young, Regina M., Scholler, John, Gill, Saar I., June, Carl H., Grupp, Stephan A., Lacey, Simon F., Melenhorst, J. Joseph·2018·Nature Medicine

DOI 10.1038/s41591-018-0201-9PMC PMC6511988

Open this paper in CoChat — free account

Abstract

We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0201-9

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citation
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citation
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation

Show all 36 references

Research works printed but not linked: 1

Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Clin. Cancer Res. 8, 995–1002 (2002).

Sorted by citations

Items 201–300 of 659

Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy
Bohineust, A., Tourret, M., Lew‐Derivry, L., & Caillat‐Zucman, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.07.003 · Cited by 41
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
Du, J., & Zhang, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03198-7 · Cited by 37
Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics
Scheller, J., Engelowski, E., Moll, J. M., & Floss, D. M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.001 · Cited by 37
Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations
Wang, Z., Gagliardi, M., Mohamadi, R. M., Ahmed, S. U., Labib, M., Zhang, L., Popescu, S., Zhou, Y., Sargent, E. H., Keller, G. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay7629 · Cited by 37
Toward “off‐the‐shelf” allogeneic CAR T cells
Aftab, B. T., Sasu, B. J., Krishnamurthy, J., Gschweng, E. H., Alcazer, V., & Depil, S. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.86 · Cited by 40
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Ghilardi, G., Brændstrup, P., Chong, E. A., Schuster, S. J., Svoboda, J., & Ruella, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17191 · Cited by 38
Self-citation
Donor T cells for CAR T cell therapy
Tang, T. C. Y., Xu, N., Nordon, R. E., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2022) · Biomarker Research · doi:10.1186/s40364-022-00359-3 · Cited by 43
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla, P. A., & Atilla, E. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101459 · Cited by 37
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
Caballero, A. C., Escribà-García, L., Álvarez‐Fernández, C., & Briones, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904497 · Cited by 39
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
Wall, D. A., & Krueger, J. (2020) · Current Oncology · doi:10.3747/co.27.5283 · Cited by 36
Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells
Fleischer, L. C., Becker, S. A., Ryan, R. E., Fedanov, A., Doering, C. B., & Spencer, H. T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.003 · Cited by 36
Biomaterials in Chimeric Antigen Receptor T‑Cell Process Development
Cardle, I. I., Cheng, E. L., Jensen, M. C., & Pun, S. H. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00335 · Cited by 36
Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch
Warda, W., Rocha, M. N. D., Trad, R., Haderbache, R., Salma, Y., Bouquet, L., Roussel, X., Nicod, C., Deschamps, M., & Ferrand, C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00284-3 · Cited by 38
In vivo gene immunotherapy for cancer
Mai, D., June, C. H., & Sheppard, N. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3603 · Cited by 35
Self-citation
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells
Ruella, M., Barrett, D. M., Shestova, O. E., Perazzelli, J., Posey, A. D., Hong, S. J., Kozlowski, M. S., Lacey, S. F., Melenhorst, J. J., June, C. H., et al. (2019) · Blood · doi:10.1182/blood.2019001859 · Cited by 36
Self-citation
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765097 · Cited by 37
CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
Liao, C., Wang, Y., Huang, Y., Duan, Y., Liang, Y., Chen, J., Jiang, J., Shang, K., Zhou, C., Gu, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207394 · Cited by 33
Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells
Hu, D., Yang, R., Wang, G., Li, H., Fan, X., & Liang, G. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s445101 · Cited by 34
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
Lamble, A., Schultz, L., Nguyen, K., Hsieh, E. M., McNerney, K., Rouce, R., Gardner, R. A., Ghorashian, S., Shah, N. N., & Maude, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013243 · Cited by 32
Self-citation
“Off-The-Shelf” allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges
Mohty, R., & Lazaryan, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1433432 · Cited by 36
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
Alidadi, M., Barzgar, H., Zaman, M., Paevskaya, O. A., Metanat, Y., Khodabandehloo, E., & Moradi, V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1491282 · Cited by 36
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies
Chen, Y., Xin, Q., Qiu, J., Zhu, M., Li, Z., Tu, J., Tu, J., & Li, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00725-5 · Cited by 36
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01886-9 · Cited by 34
Self-citation
Expanding CAR-T cell immunotherapy horizons through microfluidics
Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34
Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44
Xu, F., Zhu, M., Qiu, F., Li, W., Wang, M., Guo, Y., Xi, X., & Du, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106991 · Cited by 32
CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
Ren, A., Tong, X., Xu, N., Zhang, T., Zhou, F., & Zhu, H. (2023) · Vaccines · doi:10.3390/vaccines11010165 · Cited by 31
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
Buechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 32
Four challenges to CAR T cells breaking the glass ceiling
Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 34
CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma
Rowan, A. G., Ponnusamy, K., Ren, H., Taylor, G. P., Cook, L. B. M., & Karadimitris, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118681 · Cited by 31
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 32
CAR-T treatment for cancer: prospects and challenges
Chen, R., Chen, L., Wang, C., Zhu, H., Gu, L., Li, Y., Xiong, X., Chen, G., & Jian, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288383 · Cited by 33
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou, I., Kalafateli, M., & Triantos, C. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052631 · Cited by 31
Drug delivery for metabolism targeted cancer immunotherapy
Khodaei, T., Inamdar, S., Suresh, A. P., & Acharya, A. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114242 · Cited by 30
Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy
Naeem, M., Hazafa, A., Bano, N., Ali, R., Farooq, M., Razak, S. I. A., Lee, T. Y., & Devaraj, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121409 · Cited by 32
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fräßle, S. P., Tschulik, C., Effenberger, M. J. P., Cletiu, V., Gerget, M., Schober, K., Busch, D. H., Germeroth, L., Stemberger, C., & Poltorak, M. P. (2023) · Communications Biology · doi:10.1038/s42003-023-04978-w · Cited by 30
The Future: In Vivo CAR T Cell Gene Therapy
Mhaidly, R., & Verhoeyen, E. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.012 · Cited by 29
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
Gardner, T. J., Bourne, C. M., Dacek, M. M., Kurtz, K. G., Malviya, M., Peraro, L., Silberman, P. C., Vogt, K. C., Unti, M. J., Brentjens, R. J., et al. (2020) · Cancers · doi:10.3390/cancers12082175 · Cited by 29
Correction to: Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
Du, J., & Zhang, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03269-9 · Cited by 29
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Nasiri, F., Kozani, P. S., Salem, F., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03697-y · Cited by 30
Cellular Immunotherapy of Canine Cancer
Addissie, S., & Klingemann, H. (2018) · Veterinary Sciences · doi:10.3390/vetsci5040100 · Cited by 28
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
Crowther, M. D., Svane, I. M., & Met, Ö. (2020) · Cells · doi:10.3390/cells9071588 · Cited by 26
CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
Ali, A. M., Goy, A. H., & Dunleavy, K. M. (2022) · Blood · doi:10.1182/blood.2022016226 · Cited by 27
Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications
Teoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 29
Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape
Chen, Y., Xin, Q., Zhu, M., Qiu, J., Qiu, J., Li, R., & Tu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01894-2 · Cited by 29
Escape From ALL-CARTaz
Zheng, S., Asnani, M., & Thomas‐Tikhonenko, A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000381 · Cited by 27
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
To, V., Evtimov, V. J., Jenkin, G., Pupovac, A., Trounson, A. O., & Boyd, R. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968395 · Cited by 29
Current state of CAR-T therapy for T-cell malignancies
Luo, L., Zhou, X., Zhou, L., Liang, Z., Yang, J., Tu, S., & Li, Y. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221143025 · Cited by 28
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
Eisenberg, V., Hoogi, S., Shamul, A., Barliya, T., & Cohen, C. J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.007 · Cited by 27
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review
Locatelli, F., Shah, B. D., Thomas, T., Velasco, K., Adedokun, B., Aldoss, I. T., Gore, L., Hoelzer, D. F., Bassan, R., Park, J. H., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2232496 · Cited by 29
Advances in manufacturing chimeric antigen receptor immune cell therapies
Ramamurthy, A., Tommasi, A. M., & Saha, K. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01019-4 · Cited by 27
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Maciocia, N., Wade, B., & Maciocia, P. M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012263 · Cited by 26
CAR-Based Approaches to Cutaneous T-Cell Lymphoma
Scarfò, I., Frigault, M. J., & Maus, M. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00259 · Cited by 26
Expansion processes for cell-based therapies
Scibona, E., & Morbidelli, M. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107455 · Cited by 29
Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
Jacoby, E. (2019) · Clinical Hematology International · doi:10.2991/chi.d.190219.001 · Cited by 26
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies
Sakemura, R. L., Cox, M. J., Hefazi, M., Siegler, E. L., & Kenderian, S. S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894648 · Cited by 25
Nanotechnology synergized immunoengineering for cancer
Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 27
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation
Laurent, C., Syrykh, C., Hamon, M., Adélaı̈de, J., Guillé, A., Escudié, F., Jalowicki, G., Fina, F., Bardet, A., Mescam, L., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001834 · Cited by 25
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
Fang, K., Lee, J., Khatri, I. A., Na, Y., & Li, Z. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007277 · Cited by 25
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
Su, J.-C., Zeng, Y., Song, Z., Liu, Y., Ou, K., Wu, Y., Huang, M., Li, Y., & Tu, S. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01745-8 · Cited by 29
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art
Abramson, J. S., Lunning, M. A., & Palomba, M. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238693 · Cited by 24
The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective
Yin, H., & Wei, X. (2025) · MedComm · doi:10.1002/mco2.70067 · Cited by 27
Extracellular vesicles as nature's nano carriers in cancer therapy: Insights toward preclinical studies and clinical applications
Wu, X., Meng, Y., Yao, Z., Lin, X., Hu, M., Cai, S., Gao, S., & Zhang, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107751 · Cited by 28
The rise of human stem cell-derived natural killer cells for cancer immunotherapy
Wang, K., Han, Y., Cho, W. C. S., & Huang, Z. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1559293 · Cited by 23
Small-molecule inducible transcriptional control in mammalian cells
Doshi, A., Sadeghi, F., Varadarajan, N., & Cirino, P. C. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1808583 · Cited by 23
Antigen Loss after Targeted Immunotherapy in Hematological Malignancies
Zhou, T., & Wang, H. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.04.005 · Cited by 23
Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
Blaeschke, F., Ortner, E., Stenger, D., Mahdawi, J., Apfelbeck, A., Habjan, N., Weißer, T., Kaeuferle, T., Willier, S. M., Kobold, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845499 · Cited by 24
Interpreting the B-cell receptor repertoire with single-cell gene expression using Benisse
Zhang, Z., Chang, W. Y., Wang, K., Yang, Y., Wang, X., Yao, C., Wu, T., Wang, L. L., & Wang, T. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00492-6 · Cited by 25
Current progress in CAR‑T cell therapy for tumor treatment (Review)
Chen, L., Xie, T., Wei, B., & Di, D.-L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13478 · Cited by 25
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
Samur, M., Samur, A. A., Corre, J., Lannes, R., Shah, P. S., Anderson, K. C., Avet‐Loiseau, H., & Munshi, N. C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010025 · Cited by 23
Recent advancement in targeted therapy and role of emerging technologies to treat cancer
Barot, S., Patel, H. J., Yadav, A., & Ban, I. (2023) · Medical Oncology · doi:10.1007/s12032-023-02184-6 · Cited by 25
The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the Sphinx?
Zhou, Z.-K., Zhang, G., Xu, Y., Yang, S., Wang, J.-J., Li, Z.-R., Peng, F., & Lu, Q. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217083 · Cited by 21
Antigen Delivery to DEC205+ Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites
Silva, M. D. O., Almeida, B. S., Sales, N. S., Diniz, M. O., Aps, L. R. M. M., Rodrigues, K. B., Silva, J. R., Moreno, A. C. R., Porchia, B. F. M. M., Sulczewski, F. B., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57038 · Cited by 22
SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
Wei, W., Ma, H., Yang, D., Sun, B., Tang, J., Zhu, Y., Chen, X., Huang, X., Liu, J., Hu, Z., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008402 · Cited by 22
Long‐term survivorship care after CAR‐T cell therapy
Puckrin, R., Jamani, K., & Jimenez-Zepeda, V. H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14100 · Cited by 26
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 24
In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma
Krug, A., Saidane, A., Martinello, C., Fusil, F., Michels, A., Buchholz, C. J., Ricci, J., & Verhoeyen, E. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03179-5 · Cited by 21
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 21
Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy
Chen, X., Gao, Q., Roshal, M., & Cherian, S. (2023) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22113 · Cited by 24
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren, J., Liao, X., Lewis, J. M., Chang, J., Qu, R., Carlson, K. R., Foss, F. M., & Girardi, M. (2024) · Nature Communications · doi:10.1038/s41467-024-44786-2 · Cited by 23
Translating Cell and Gene Biopharmaceutical Products for Health and Market Impact. Product Scaling From Clinical to Marketplace: Lessons Learned and Future Outlook
Bak, A., Friis, K. P., Wu, Y., & Ho, R. J. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.027 · Cited by 21
Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy
Bouziana, S. D., & Bouzianas, D. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103096 · Cited by 20
Axicabtagene Ciloleucel and Brexucabtagene Autoleucel in Relapsed and Refractory Diffuse Large B-Cell and Mantle Cell Lymphomas
Reagan, P. M., & Friedberg, J. W. (2021) · Future Oncology · doi:10.2217/fon-2020-0291 · Cited by 21
State-of-Art of Cellular Therapy for Acute Leukemia
Lee, J. B., Vasić, D., Kang, H., Fang, K., & Li, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094590 · Cited by 22
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
Leyfman, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0685-x · Cited by 24
From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy
Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 25
Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells
Fang, Y., Zhang, Y., Guo, C., Chen, C., Gao, H., Zhou, X., Liu, T., & Qian, Q. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.008 · Cited by 21
CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering
Panagopoulou, T. I., & Rafiq, Q. A. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.06.010 · Cited by 20
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL –Induced B-Cell Acute Lymphoblastic Leukemia
Yang, L., Qiu, Q., Tang, M., Wang, F., Yi, Y., Yi, D., Yang, Z., Zhu, Z., Zheng, S., Yang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0516 · Cited by 21
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors
Mohty, R., & Gauthier, J. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01420-9 · Cited by 20
Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
Cordes, N., Kolbe, C., Lock, D., Holzer, T., Althoff, D., Schaefer, D., Blaeschke, F., Kotter, B., Karitzky, S., Rössig, C., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.013 · Cited by 19
Adoptive Cell Therapy for T-Cell Malignancies
Fang, K., Lee, J. B., & Li, Z. (2022) · Cancers · doi:10.3390/cancers15010094 · Cited by 20
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts
Berg, P., Ruppert‐Seipp, G., Müller, S., Maurer, G. D., Hartmann, J., Holtick, U., Buchholz, C. J., & Funk, M. B. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00183-2 · Cited by 20
Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia
Cao, J., Cheng, H., Shi, M., Wang, G., Chen, W., Qi, K., Li, H., Qiao, J., Zhao, J., Wu, Q., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0516-7 · Cited by 19
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 20
Ultrasensitive Detection and Depletion of Rare Leukemic B Cells in T Cell Populations via Immunomagnetic Cell Ranking
Wang, Z., Sargent, E. H., & Kelley, S. O. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04202 · Cited by 19
iPSCs in NK Cell Manufacturing and NKEV Development
Boyd-Gibbins, N., Karagiannis, P., Hwang, D. W., & Kim, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890894 · Cited by 18
In vivo CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address
Wakao, R., & Fukaya‐Shiba, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1141880 · Cited by 18
Chimeric antigen receptor T‐cells: Properties, production, and quality control
Ramesh, P., Hui, H. Y. L., Brownrigg, L., Fuller, K., & Erber, W. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14121 · Cited by 16
Advances in nano-immunotherapy for hematological malignancies
Xu, J., Liu, W., Fan, F., Zhang, B., Sun, C., & Hu, Y. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00525-3 · Cited by 21
Self-citation

Authors: Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., & Melenhorst, J. J.
Affiliations: Abramson Cancer Center (US)
Children's Hospital of Philadelphia (US)
University of Pennsylvania (US)
Children's Hospital Colorado (US)
Corresponding author: June, Carl H.
Melenhorst, J. Joseph
ORCID: Ruella, Marco
Xu, Jun
Barrett, David M.
Fraietta, Joseph A.
Reich, Tyler J.
Klichinsky, Michael
Patel, Prachi R.
Kulikovskaya, Irina
Bhoj, Vijay G.
Orlando, Elena J.
Fry, Terry J.
Bitter, Hans
Maude, Shannon L.
Levine, Bruce L.
Nobles, Christopher L.
Bushman, Frederic D.
Young, Regina M.
Scholler, John
Gill, Saar I.
June, Carl H.
Grupp, Stephan A.
Lacey, Simon F.
Melenhorst, J. Joseph
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2018-10
Volume: 24
Issue: 10
Pages: 1499-1503
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-018-0201-9
PMC: PMC6511988
OpenAlex: W2893691711
Cited by: 659
References: 36
Citations by year: 2026: 61 · 2025: 73 · 2024: 83 · 2023: 84 · 2022: 83 · 2021: 91 · 2020: 91 · 2019: 78 · 2018: 14
FWCI: 25.75
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K99CA212302, R00CA212302, T32CA009140, R01CA120409, P01CA214278)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords: CAR T-cell therapy, CD19, tisagenlecleucel, B-cell acute lymphoblastic leukemia, CAR T cell manufacturing, relapse
MeSH terms: Receptors, Chimeric Antigen, Adult, Epitopes, B-Lymphocytes, Humans, Leukemia, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Antigens, CD19, Drug Resistance, Neoplasm, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks